[go: up one dir, main page]

ZA200903652B - Methods for treating disruptive behavior disorders - Google Patents

Methods for treating disruptive behavior disorders

Info

Publication number
ZA200903652B
ZA200903652B ZA200903652A ZA200903652A ZA200903652B ZA 200903652 B ZA200903652 B ZA 200903652B ZA 200903652 A ZA200903652 A ZA 200903652A ZA 200903652 A ZA200903652 A ZA 200903652A ZA 200903652 B ZA200903652 B ZA 200903652B
Authority
ZA
South Africa
Prior art keywords
disruptive behavior
behavior disorders
methods
disorder
therapy
Prior art date
Application number
ZA200903652A
Other languages
English (en)
Inventor
Magali Haas
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ZA200903652B publication Critical patent/ZA200903652B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA200903652A 2006-10-27 2009-05-26 Methods for treating disruptive behavior disorders ZA200903652B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86313706P 2006-10-27 2006-10-27

Publications (1)

Publication Number Publication Date
ZA200903652B true ZA200903652B (en) 2010-08-25

Family

ID=39469514

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200903652A ZA200903652B (en) 2006-10-27 2009-05-26 Methods for treating disruptive behavior disorders

Country Status (19)

Country Link
US (1) US20080103127A1 (xx)
EP (1) EP2089015B1 (xx)
JP (1) JP2010508279A (xx)
KR (1) KR20090088379A (xx)
CN (1) CN101646432A (xx)
AT (1) ATE489083T1 (xx)
AU (1) AU2007329779A1 (xx)
BR (1) BRPI0718318A2 (xx)
CA (1) CA2667510A1 (xx)
CO (1) CO6160292A2 (xx)
DE (1) DE602007010818D1 (xx)
EA (1) EA015690B1 (xx)
ES (1) ES2354319T3 (xx)
IL (1) IL198396A0 (xx)
MX (1) MX2009004552A (xx)
NO (1) NO20091659L (xx)
SV (1) SV2009003241A (xx)
WO (1) WO2008070277A2 (xx)
ZA (1) ZA200903652B (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
TWI636784B (zh) * 2011-04-05 2018-10-01 大塚製藥股份有限公司 含7-〔4-(4-苯並〔b〕噻吩-4-基-哌-1-基)丁氧基〕-1H-喹啉-2-酮之醫藥組成物與套組，以及彼之用途
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2020212951A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
SK286621B6 (sk) * 1999-08-20 2009-02-05 Ortho-Mcneil Pharmaceutical, Inc. Farmaceutický prostriedok obsahujúci kombináciu tramadolového materiálu a antikonvulzívneho činidla, táto kombinácia a jej použitie na výrobu liečiva
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
CA2439286A1 (en) * 2001-02-27 2002-09-06 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating anxiety disorders

Also Published As

Publication number Publication date
EP2089015B1 (en) 2010-11-24
JP2010508279A (ja) 2010-03-18
ES2354319T3 (es) 2011-03-14
AU2007329779A1 (en) 2008-06-12
DE602007010818D1 (de) 2011-01-05
US20080103127A1 (en) 2008-05-01
WO2008070277A2 (en) 2008-06-12
IL198396A0 (en) 2010-02-17
ATE489083T1 (de) 2010-12-15
BRPI0718318A2 (pt) 2013-11-26
CA2667510A1 (en) 2008-06-12
KR20090088379A (ko) 2009-08-19
EA200970425A1 (ru) 2009-12-30
NO20091659L (no) 2009-05-26
CO6160292A2 (es) 2010-05-20
EA015690B1 (ru) 2011-10-31
MX2009004552A (es) 2009-11-10
EP2089015A2 (en) 2009-08-19
SV2009003241A (es) 2010-04-15
CN101646432A (zh) 2010-02-10
WO2008070277A3 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
TW200602048A (en) Diphenylimidazopyrimidine and -imidazole amines as inhibitors of β -secretase
WO2008022024A3 (en) Imidazole amines as inhibitors of beta-secretase
EA200601746A1 (ru) Применение ротиготина для лечения и предупреждения синдрома "паркинсонизм-плюс"
WO2007137164A3 (en) Co-therapy for the treatment of epilepsy and related disorders
BRPI0512213A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
WO2006113942A3 (en) Method of inhibiting cathepsin activity
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
MX2009004798A (es) Tratamiento de los trastornos generalizados del desarrollo.
WO2007112345A8 (en) Use of cyclosporin alkene analogues for preventing or treating viral-induced disorders
BRPI0510094A (pt) uso de flibanserina no tratamento pré-menstrual e outros distúrbios sexuais femininos
SI2205244T1 (sl) Postopki dajanja N-(5-terc.-butil-izoksazol-3-il)-N'-(4-(7-(2-morfolin- 4-il-etoksi-)imidazo-2,1-b)-(1,3)-benzotiazol-2-il)-fenil)sečnine za zdravljenje proliferativne bolezni
WO2007112357A3 (en) Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
WO2012002687A3 (en) Methods for treating bipolar disorder
MX2009004770A (es) Compuestos de carbamato para usarse en el tratamiento de la depresion.
EP2416795A4 (en) COGNITIVE DECLINE INHIBITORS
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
ZA200903652B (en) Methods for treating disruptive behavior disorders
WO2007136741A3 (en) N-desmethyl-doxepin and methods of using the same to treat sleep disorders
NZ606276A (en) Fastening Means
WO2010019701A3 (en) Diaryl urea derivatives
WO2010005585A3 (en) 4-aminoquinazoline prodrugs
WO2009131850A3 (en) Pai-1 expression and activity inhibitors for the treatment of ocular disorders
WO2008018639A3 (en) Glycine transporter inhibitor